REFLAB ApS: Financial statements 2020
CVR: 15322586
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
REFLAB ApS (CVR 15322586) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK 1,851,080 and a net result of DKK -888,467 compared with DKK 3,073,850 the year before. That is a decrease of 73.1% compared with the year before. Equity in the 2020 report amounted to DKK 2,427,864. The solvency ratio was 38.9%. The company had 6 employees in the financial year.
- Gross Profit
- DKK 1,851,080
- Profit/Loss
- DKK -888,467
- Equity
- DKK 2,427,864
- Total Assets
- DKK 6,241,235
- Employees
- 6
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | 1.9 mio. | -888 t. | 2.4 mio. | 6 |
| 2019 | - | 6.9 mio. | 3.1 mio. | 3.3 mio. | 6 |
| 2018 | - | 3.3 mio. | -426 t. | 242 t. | 8 |
| 2017 | - | 2.8 mio. | -1 mio. | 669 t. | 7 |
| 2016 | - | 1.7 mio. | -1.8 mio. | 1.7 mio. | 6 |
Official annual report
How creditworthy is REFLAB ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
REFLAB ApS has published its annual report for 2019. Gross profit came to DKK 6,890,900, and the net result was DKK 3,073,850.
About REFLAB ApS
REFLAB ApS is a Danish company of the type Anpartsselskab based in Hvidovre, founded in 1991. The company is registered under the industry Traditionelle, komplementære og alternative behandlingsformer. The company was previously named REFERENCELABORATORIET ApS. The management consists of Gert Pynt Andersen and Katrine Baumann Markussen. The company is owned by R-Biopharm AG. The company has 7 employees (2018). In 2025, the company reported a gross profit of DKK 4,582,184 and a net result of DKK -1,792,430 compared with DKK 652,577 the year before. Equity in the 2025 report amounted to DKK -635,048.